Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Sativa Investments buys UK medicinal cannabis lab for £435K

“PhytoVista provides a UK-based laboratory facility available to all jurisdictions already testing CBD products commercially, and of course able to service the UK market if and when regulatory changes hit the UK too," said Sativa executive director Mark Blower
cannabis
Sativa says the purchase price was below the market value of assets and equipment

Sativa Investments PLC (NEX:SATI) has agreed to buy PhytoVista Laboratories, a UK-based lab that tests cannabis oils and hemp products, for £435,000.

The British medicinal cannabis investment vehicle will pay £235,000 in cash and £200,000 worth of shares at 0.04p per share to buy PhytoVista from Carbon Managers Limited.

READ: Sativa Investments positions itself for 'huge opportunity' in medicinal cannabis

Carbon is wholly owned by Sativa’s chief executive Geremy Thomas but he was not involved in the decision-making for the deal.

Sativa independent directors Noel Lyons and Mark Blower assessed the deal and consulted Dr. Stuart Ungar, who is a member of the company's medicinal cannabis advisory board.

Sativa said the purchase price was well below the market value of the assets and equipment acquired. If purchased new, the equipment laboratory would cost more than £580,000, the company said.

“Every batch of medicinal cannabis including CBD oil requires stringent testing, including for cannabinoids, pesticides, heavy metals and mycotoxins, along with full testing for terpenes, residual solvents and microbiology,” Blower said.

“PhytoVista provides a UK-based laboratory facility available to all jurisdictions already testing CBD products commercially, and of course able to service the UK market if and when regulatory changes hit the UK too."

PhytoVista has preferred partner status to the UK's Cannabis Trades Association for batch testing of medicinal cannabis products.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full SATI profile View Profile

Sativa Investments Timeline

Related Articles

cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
1528305384_Untitled-design-(3).jpg
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use